![InnerPageHeaderImg_BGinitiative_3](http://drjosephgathe.com/wpsite/wp-content/uploads/2021/06/InnerPageHeaderImg_BGinitiative_3.png)
BGB-3111 (COVID)
The primary objective of this study is to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019 (COVID-19) and pulmonary distress.
For more information on this clinical trail Click Here.